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MinireviewParsing Ink4a/Arf:
“Pure” p16-Null Mice
thereby specifying two distinct proteins that bear no
amino acid homology to one another. Since the gene
encoding p16INK4a was the first of the two to be identified,
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the alternative reading frame protein was designatedSaint Jude Children’s Research Hospital
ARF. (The HUGO nomenclature is CDKN2A, formerly332 North Lauderdale
used to designate the entire locus but now only theMemphis, Tennessee 38117
INK4a “gene”; MDM2S1 is the tentative designation for
ARF.)
The retinoblastoma protein (pRB) and p53 transcription Without knowledge of the Arf gene at the time they
factor are frequently deregulated in human tumors. In initiated their experiments, and with an understanding
normal mammalian cells, the growth suppressive func- that mutations in cancer cells frequently target exon 2
tions of pRB are inactivated though phosphorylation in of the human INK4a gene, Serrano and coworkers (1996)
the G1 phase of the cell division cycle. These periodic ablated exon 2 of the Ink4a gene in the mouse germ
modifications of pRB (and of two other pRB family mem- line, inadvertently disrupting both the p16Ink4a and p19Arf
bers, p130 and p107) are executed by the cyclin reading frames. “Ink4a” null animals were born at the
D-dependent kinases, Cdk4 and Cdk6, together with the expected Mendelian ratio, had no apparent morphologic
cyclin E-dependent kinase, Cdk2, thereby controlling or behavioral defects, and developed normally. How-
the cell’s entry into the DNA synthetic (S) phase of the ever, they were strikingly prone to spontaneous tumor
cell cycle (Weinberg, 1995). Phosphorylation of pRB late development. Moreover, mouse embryo fibroblasts
in G1 phase cancels its ability to bind to and inhibit the (MEFs) isolated from midgestation embryos proliferated
activities of E2F transcription factors, which, when freed more rapidly in culture than their wild-type counterparts,
from pRB, activate gene products that govern nucleo- did not senesce during continuous passage, and could
tide metabolism and DNA synthesis. Like pRB, the p53 be transformed directly by oncogenic Ha-Ras without
transcription factor also negatively regulates cell cycle a requirement for cotransformation by so-called “im-
progression, but principally in response to cellular mortalizing oncogenes” such as Myc or adenovirus E1A.
stresses, such as DNA damage, hypoxia, and oncogene In short, these MEFs exhibited properties of established
activation (Levine, 1997). Signal transduction pathways cell lines rather than those of early passage primary
activated in stressed cells trigger phosphorylation and fibroblast cultures. Quite understandably, these proper-
acetylation of p53, leading to its stabilization and to the ties were ascribed to p16Ink4a loss.
initiation of a p53-dependent transcriptional program Disruption of exon 1 in the mouse germ line was
that either halts cell proliferation or, more dramatically, subsequently used to generate mice lacking p19Arf alone
induces cell suicide. Among the p53-responsive genes (Kamijo et al., 1997). Despite the fact that these animals
continued to express abundant levels of p16Ink4a, Arf nullis Hdm2 (Mdm2 in the mouse), which acts in a negative
mice exhibited all of the cardinal properties of thefeedback loop to quench p53 transcription and acceler-
“Ink4a” null strain (which will be designated Ink4a/Arfate p53 degradation. Other p53-responsive genes arrest
null in the discussion that follows). This raised the unex-cell cycle progression and modulate the apoptotic ma-
pected possibility that tumor development in vivo andchinery.
the properties of cultured MEFs in vitro that were firstSurprisingly, two products of the INK4a/ARF locus,
ascribed to Ink4a disruption instead reflected loss ofwhose functions are also disrupted in a wide variety of
Arf. What, then, is the phenotype of mice lacking p16Ink4ahuman cancers, indirectly regulate the activities of both
alone? Two papers in the September 6 issue of NaturepRB and p53. The INK4a/ARF locus is unusual in several
now reveal welcome answers that resolve many of therespects (see Figure 1). First, it encodes two functionally
remaining ambiguities (Krimpenfort et al., 2001; Sharplessunrelated proteins, p16INK4a and p14ARF (p19Arf in the
et al., 2001).mouse), both of which are potent inhibitors of cell prolif-
A “Pure” p16Ink4a Knockouteration (Serrano et al., 1993; Quelle et al., 1995). The
Two groups have now used different strategies to ablatep16INK4a protein inhibits Cdk4 and Cdk6, thereby main-
Ink4a in the mouse germ line, leaving Arf intact. Mem-taining pRB in its active, growth-suppressive form and
bers of Anton Berns’s laboratory chose to “knock in” aarresting cells in G1 phase. In contrast, p14ARF interacts
point mutated Ink4a allele, thereby replacing the wild-directly with Hdm2 to stabilize and activate p53. De-
type gene with an altered form containing a translationalpending on the cell type and collateral signaling, ARF
termination codon at amino acid 101 (Krimpenfort et al.,can either trigger arrest in both the G1 and G2 phases of
2001). The point mutation does not affect the amino acidthe cell cycle or modulate p53’s proapoptotic functions.
composition of Arf. The analogous mutation is widelyEven more surprising is the manner by which the INK4a
represented in human tumors, and it leads to the produc-and ARF gene products are encoded. RNAs transcribed
tion of a misfolded and unstable polypeptide that isfrom alternative first exons (1 and 1, for INK4a and
defective in inhibiting cyclin D-dependent kinases inARF, respectively) are spliced to a common second
vitro and in inducing cell cycle arrest in vivo. Enforcedexon, which is translated in alternative reading frames,
expression of the mutant Ink4a allele in human U20S
osteosarcoma cells did not arrest them in G1 phase. In
agreement with expectations, a truncated version of1 Correspondence: sherr@stjude.org
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pressed in mouse embryos, both are induced when
MEFs are explanted into culture, and both proteins ac-
cumulate as the proliferation rates of passaged cells
decline (Zindy et al., 1998). Stress imposed by the culture
environment per se rather than a mitotic timer, such as
telomere shortening, seems to be largely responsible
for replicative senescence in rodent fibroblasts (Sherr
and DePinho, 2000). Introduction and overexpression
of an activated Ras oncogene in primary rodent cells
accelerates cellular senescence (Serrano et al., 1997),
whereas the loss of Ink4a/Arf or Arf alone renders cells
susceptible to Ras transformation (Serrano et al., 1996;
Kamijo et al., 1997).
From the recent work, it is now clear that MEFs lacking
Ink4a and expressing p19Arf have none of the properties
Figure 1. Structure and Function of the Ink4a/Arf Locus conferred by Arf loss alone (see Table 1). Specifically,
Ink4a null MEFs proliferate normally in culture, exhibit(A) The two products of the Ink4a/Arf locus, p16Ink4a and p19Arf (p14ARF
in humans) regulate the Rb and p53 pathways, respectively. unchanged cell cycle profiles and cell size, arrest prop-
(B) Alternative first exons (1 and 1) transcribed from different erly in response to serum deprivation or ionizing radia-
promoters (arrows) specify the 5 ends of the Ink4a and Arf tran- tion, and do not have any advantage in forming colonies
scripts, respectively. These are spliced to the same acceptor site
when plated at low density. The Ink4a null MEFs senescein exon 2, which is translated in alternative frames. Ink4a coding
when passaged on a 3T3 or 3T9 protocol, and cannotsequences in exons 1, 2, and 3 are denoted by light shading, while
be transformed by oncogenic Ras alone. Krimpenfort etArf coding sequences in exons 1 and 2 are indicated by dark
shading. The regions disrupted in the different knockout mouse al. saw no effects of Ink4a loss on the rates of spontane-
strains are indicated below the figure. The schematic is not drawn ous establishment of permanent cell lines, which exhib-
to scale, and in both the human and mouse genomes, exons 1 ited either p53 mutations or Arf deletions typical of cell
and 1 are separated by 15 kb. (Adapted from Quelle et al., 1995). lines derived from wild-type primary MEFs (Kamijo et al.,
1997 and references therein). Sharpless and coworkers
reported that Ink4a null MEFs are 2-fold more sensitivep16Ink4a could not be detected in MEFs from the mutant
to cotransformation by Myc and Ras and gave rise toanimals (designated Ink4a*/* in this study), whereas
immortalized variants at a somewhat faster rate thanp19Arf levels were unaffected. Krimpenfort and cowork-
their wild-type counterparts when passaged on a 3T9ers independently derived an additional deletion strain
protocol, yielding some established cell lines that pre-of Ink4a/Arf null mice lacking exons 2 and 3, so that any
served both wild-type p53 and Arf. Thus, while all agreedifferences in phenotype between these animals and
that loss of p16Ink4a alone is insufficient for immortaliza-their “pure” Ink4a mutant strain would logically reflect
tion of MEFs, its absence may facilitate their escape
effects of the Ink4a alleles, and not strain-specific ge-
from senescence, as has been previously suggested
netic modifiers. Ronald DePinho’s group instead deleted
from studies carried out using excisable Ink4a and Arf
exon 1, removing the translation initiation codon and
retroviral antisense vectors (Carnero et al., 2000).
35 codons of Ink4a, and then excising the neomycin- Experiments such as these raise the question of
resistance gene used for selection in embryonic stem whether different cell types may be “wired” differently
cells, ultimately leaving all splice sites and cis-regulatory with respect to their reliance on the Rb and p53 path-
sequences intact (Sharpless et al., 2001). After examin- ways for senescence, or whether INK4a is a more impor-
ing many independently derived primary MEF cultures tant regulator of this phenomenon in humans than in
from their Ink4a null mice, they also concluded that mice. There is some recent support for the former idea
expression of p19Arf was unaffected by exon 1 deletion. in experiments performed with cultured mouse bone
Although the results obtained by the two groups were marrow-derived pre-B cells and macrophages, which
quite similar, there were also a few notable differences were found to differ in their reliance on Ink4a and Arf
in the severity of certain phenotypes (summarized in loss for establishment in culture (Randle et al., 2001).
Table 1 and discussed below). Apart from use of differ- Sharpless et al. report that Ink4a deletion results in thy-
ent ES cell lines (129/Ola [Berns] versus 129/Sv [De- mocyte hypercellularity in vivo and endows cultured
Pinho]) and the mixed genetic backgrounds of the in- mitogen-stimulated splenic T cells with an increased
terbred mice, it cannot be formally excluded that the proliferative potential, indicating that p16Ink4a gates pro-
Ink4a*/* mutant might be hypomorphic, or, alternatively, liferation of such cells. Although most experiments
that deletion of Ink4a exon 1 might have subtle effects assaying Ink4a and Arf function in the mouse have ex-
on Arf transcription or splicing. ploited fibroblasts, work in humans has also utilized
A Muted Role for Ink4a in Cellular Senescence primary epithelial cells, such as keratinocytes or mouse
Explanting primary mammalian cells into culture ulti- mammary epithelial cells, in which cancellation of
mately leads to a senescent state in which cells perma- p16INK4a function has been found to be important in im-
nently exit the division cycle but remain viable for ex- mortalization (Reznikoff et al., 1996; Kiyono et al., 1998).
tended periods of time. The p16INK4a protein has been Some have suggested that INK4a may function as a
broadly implicated as a regulator of this phenomenon timer to count cell divisions. However, this view has
in both human and mouse cells (Ruas and Peters, 1998). been challenged by recent results indicating that cell
culture conditions and not the number of populationAlthough neither p16Ink4a nor p19Arf are detectably ex-
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Table 1. Comparative Phenotypes of Mice Lacking Ink4a and/or Arf 1
Ink4a/Arf exons 2,3 Arf exon 1 Ink4a mutant Ink4a exon 1
Unusually rapid MEF Unusually rapid MEF Normal MEF proliferation rate. Normal MEF proliferation rate.
proliferation rate. proliferation rate.
MEFs are immortal and MEFs are immortal and MEFs undergo senescence and MEFs undergo senescence and
susceptible to transformation susceptible to transformation resist transformation by resist transformation by
by oncogenic Ras. by oncogenic Ras. oncogenic Ras. oncogenic Ras. Spontaneous
immortalization occurs at an
accelerated rate.
Spontaneous tumors Spontaneous tumors (50% No spontaneous tumors seen in Spontaneous tumor incidence in
(predominantly sarcomas and sarcomas, 25% lymphomas, the first year of life. the first year of life is 25%
lymphomas) appear with a mean 25% carcinomas, plus tumors (mostly sarcomas and
latency of 34 weeks. Tumor of central nervous system) lymphomas). Many animals
incidence is accelerated after appear with a mean latency of develop skin and lung tumors
neonatal treatment of mice 38 weeks. Tumor incidence is after carcinogen treatment.
with DMBA or X-rays. accelerated after neonatal
treatment of mice with DMBA
or X-rays.
Acceleration of Myc-induced Acceleration of Myc-induced No acceleration of Myc-induced Not tested.
B-cell lymphomagenesis. B-cell lymphomagenesis. B-cell lymphomagenesis.
No spontaneous melanoma. No spontaneous melanoma. Melanomas (and other tumors) Low incidence of spontaneous
appear when one copy of Arf melanoma.
is also deleted.
1 Data from Serrano et al., 1996; Kamijo et al., 1997; Krimpenfort et al., 2001; and Sharpless et al., 2001.
doublings per se determine the kinetics of p16INK4a induc- it was epigenetically silenced, as has been frequently
observed in human nonsmall cell lung carcinomas.tion in these human cell types (Ramirez et al., 2001).
Importantly, none of the latter results negate the idea Sharpless et al. therefore conclude that p16Ink4a plays an
important role in tumor suppression after carcinogenthat INK4a might help to counter the effects of proto-
oncogenic signals in vivo. exposure.
As Krimpenfort and coworkers point out, deletion ofMouse Ink4a Is a Tumor Suppressor
The Ink4a*/* strain showed only a subtle predisposition one copy of the entire Ink4a/Arf locus combined with an
intragenic inactivating mutation in the remaining Ink4atoward spontaneous tumor development within 17
months after birth, yielding B-cell lymphomas in two allele on the homologous chromosome occurs fre-
quently in several forms of human cancer. They modeledmice within a small cohort of only a dozen animals.
Knowing that BALB/c mice, which express a hypomor- these events in the mouse by crossing their Ink4a*/*
mice with those lacking Ink4a/Arf. Despite the fact thatphic variant of p16Ink4a (Zhang et al., 1998), are particu-
larly susceptible to pristane-induced plasmacytomas, the incidence of spontaneous tumor formation was quite
low in their Ink4a*/* animals, the Ink4a*/Arf –Ink4a/Krimpenfort et al. crossed their mice to a transgenic
strain expressing Myc under the control of a B-cell- Arf  animals all developed tumors with a mean latency
of one year, some of which were melanomas. Intrigu-specific immunoglobulin promoter-enhancer. However,
B-cell lymphomagenesis was not accelerated, consis- ingly, the mutant Ink4a* allele was maintained in these
tumors, and the linked wild-type Arf allele was not si-tent with the idea that p16Ink4a acts “upstream” of Myc
in limiting cell proliferation. Sharpless et al. detected a lenced. Neonatal treatment of Ink4a*/Arf –Ink4a/Arf 
mice with DMBA yielded highly aggressive melanomasmore robust cancer-prone phenotype with 10 of 39 of
their Ink4a/ mice developing sarcomas, lymphomas, in half these animals which again retained the single
Arf allele. By contrast, tumors arising in Ink4a/Arf/and a single melanoma within the first year of life. In a
different genetic background, Arf-null mice spontane- heterozygotes sustained deletion of the remaining wild-
type Ink4a/Arf locus. Therefore, Ink4a can cooperateously develop sarcomas, lymphomas, gliomas, and car-
cinomas at a faster rate with a mean latency of 38 weeks. with Arf heterozygosity to yield a wide spectrum of tu-
mors. Strikingly, in this context, Arf seems to be haploin-When treated with carcinogens, Ink4a null mice de-
velop a broader spectrum of tumors at a more rapid sufficient for tumor suppression. The very first evidence
that INK4a was a human tumor suppressor came fromrate than that observed for similarly treated wild-type
littermates. In the study of Sharpless et al., two addi- reverse genetic studies that fingered mutant p16INK4a in
familial human melanoma (Kamb et al., 1994). As Bernstional animals (7% of this group) developed melanomas
(also see below), whereas others mostly developed skin and colleagues indicate, their mouse model mimics the
human syndrome.and lung tumors after treatment, consistent with the
known targeting effects of the carcinogens used. Inter- The INK4a and ARF Connection
The proximity of the INK4a and ARF genes carries anestingly, p16Ink4a expression was not detected in aggres-
sive lung tumors that arose in Ink4/mice treated with obvious risk in the sense that deletions in this chromo-
somal region will cancel the functions of both tumordimethylbenzanthracene (DMBA). The wild-type Ink4a
allele was not segregated from these tumor cells, but suppressors. We still have no explanation for why the
Cell
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two genes overlap structurally. Their unusually intimate
relationship suggests that INK4a and ARF might be co-
regulated, but so far, this is true only in the sense that
both are induced when primary cells are explanted into
culture. A previous genetic analysis revealed that the
two genes might functionally interact in governing repli-
cative senescence (Carnero et al., 2000). Moreover, the
two proteins have the potential to coordinate signaling
through the RB and p53 pathways, because ARF can
be induced by E2F transcription factors whose activities
are subject to RB-negative regulation (Bates et al., 1998).
We do not fully understand these relationships, although
they provide evidence for the existence of a signaling
network that is central to tumor formation.
The finding that melanomas arise preferentially in the
background of Ink4a loss and Arf heterozygosity is a
great surprise, which suggests a novel relationship be-
tween these genes. Like mice lacking Ink4a/Arf, neither
Arf-null nor p53-null mice spontaneously develop mela-
noma. Presumably, it is the level of p19Arf that influences
the biologic response to p16Ink4a loss of function in mela-
nocytes. There is great subtlety here, and those who
harbor doubts that animal models can be used to repli-
cate human cancer syndromes should take heed.
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